The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Transformed cells have properties that allow them to survive and proliferate inappropriately. These characteristics often arise as a result of mutations caused by DNA damage. p53 suppresses transformation by removing the proliferative or survival capacity of cells with DNA damage or inappropriate cell-cycle progression. Cellular senescence, marked by morphological and gene expression changes, is a critical component of p53-mediated tumor suppression. In response to stress, p53 can facilitate an arrest and senescence program in cells exposed to stresses such as DNA damage and oncogene activation, preventing transformation. Senescent cells are evident in precancerous adenoma-type lesions, whereas proliferating, malignant tumors have bypassed senescence, either by p53 mutation or inactivation of the p53 pathway by other means. Tumors that have retained wild-type p53 often show a p53-mediated senescence response to chemotherapy. This response is actually detrimental in some tumor types, as senescent cells can drive relapse by persisting and producing cytokines and chemokines through an acquired secretory phenotype.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 8×
“The viral oncogenes used to inactivate p53 required additional Rb inactivation to bypass OIS (Serrano et al. 1997).”
BackgroundInfluentialA DNA damage checkpoint response in telomere-initiated senescence
Fagagna, F. D. D., Reaper, P. M., Clay-Farrace, L., Fiegler, H., Carr, P., von Zglinicki, T., Saretzki, G., Carter, N. P., & Jackson, S. P. (2003) · Nature · doi:10.1038/nature02118 · Cited by 2,917 · cited 2×
“As telomeres shorten, eventually a DNA damage signal is detected (d’Adda di Fagagna et al. 2003; von Zglinicki et al. 2005) and a classical DNA damage response is initiated (von Zglinicki et al. 2005).”
Backgroundp53 is required for radiation-induced apoptosis in mouse thymocytes
Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., & Jacks, T. (1993) · Nature · doi:10.1038/362847a0 · Cited by 2,864
Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473
Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379 · cited 1×
“Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a026112 9 w w w .p er sp ec ti ve si n m ed ic in e. o rg et al. 2012; Canino et al. 2012).”
BackgroundInfluentialRb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence
Narita, M., Nuñez, S., Heard, E., Narita, M., Lin, A. W., Hearn, S. A., Spector, D. L., Hannon, G. J., & Lowe, S. W. (2003) · Cell · doi:10.1016/s0092-8674(03)00401-x · Cited by 2,278 · cited 2×
“This allows the RB family of proteins to recruit chromatin modifiers that silence expression of genes that drive cellcycle progression (Ferreira et al. 2001; Narita et al. 2003).”
BackgroundBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096 · cited 1×
“Eventually, immortal clonal populations will emerge that can maintain telomere length (Neufeld et al. 1987; Counter et al. 1992).”
BackgroundOncogene-Induced Senescence Relayed by an Interleukin-Dependent Inflammatory Network
Kuilman, T., Michaloglou, C., Vredeveld, L. C. W., Douma, S., van Doorn, R., Desmet, C. J., Aarden, L. A., Mooi, W. J., & Peeper, D. S. (2008) · Cell · doi:10.1016/j.cell.2008.03.039 · Cited by 2,086 · cited 3×
“As an example of careful identification of senescence, in serial histological tissue sections of colon adenomas, senescent cells were identified by a lack of Ki67 staining combined with positive staining for p16 and the SASP factor interleukin (IL)-8, although proliferating, nonsenescent regions of the adenomas staine…”
BackgroundActivation of the ATM Kinase by Ionizing Radiation and Phosphorylation of p53
Canman, C. E., Lim, D.-S., Cimprich, K. A., Taya, Y., Tamai, K., Sakaguchi, K., Appella, E., Kastan, M. B., & Siliciano, J. D. (1998) · Science · doi:10.1126/science.281.5383.1677 · Cited by 2,042
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints
Bartkova, J., Rezaei, N., Liontos, M., Karakaidos, P., Kletsas, D., Issaeva, N., Vassiliou, L.-V. F., Kolettas, E., Niforou, K., Zoumpourlis, V. C., et al. (2006) · Nature · doi:10.1038/nature05268 · Cited by 1,986 · cited 1×
“Other oncogenic signals such as those from c-Mos and the Bcr-Abl fusion protein can induce senescence, although p53 dependence was not examined in these studies (Bartkova et al. 2006; Wajapeyee et al. 2010).”
BackgroundChemokine signaling via the CXCR2 receptor reinforces senescence
Acosta, J. C., O'Loghlen, A., Banito, A., Guijarro, M. V., Augert, A., Raguz, S., Fumagalli, M., Da Costa, M., Brown, C., Popov, N., et al. (2008) · Cell · doi:10.1016/j.cell.2008.03.038 · Cited by 1,801 · cited 2×
“Additionally, senescent cells secrete many cytokines and chemokines, a feature known as the senescence-associated secretory phenotype (SASP) (Acosta et al. 2008; Coppe et al. 2008; Kuilman et al. 2008; Wajapeyee et al. 2008).”
BackgroundThe RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 1×
“One well-studied target of cdks is the RB family of proteins (Sherr and McCormick 2002).”
BackgroundSenescence surveillance of pre-malignant hepatocytes limits liver cancer development
Kang, T.-W., Yevsa, T., Woller, N., Hoenicke, L., Wuestefeld, T., Dauch, D., Hohmeyer, A., Gereke, M., Rudalska, R., Potapova, A., et al. (2011) · Nature · doi:10.1038/nature10599 · Cited by 1,621 · cited 1×
“Interestingly, these senescent cells are cleared by the immune system, and failure to do so led to development of hepatocellular carcinoma (Kang et al. 2011).”
BackgroundSenescence in premalignant tumours
Collado, M., Gil, J., Efeyan, A., Guerra, C., Schuhmacher, A. J., Barradas, M., Benguría, A., Zaballos, A., Flores, J. M., Barbacid, M., et al. (2005) · Nature · doi:10.1038/436642a · Cited by 1,482 · cited 2×
“Lung adenomas were positive for the senescence markers p16, p15, and new markers discovered in the same study, Dec1 and Dcr2 (Collado et al. 2005).”
BackgroundReversal of human cellular senescence: roles of the p53 and p16 pathways
Beauséjour, C. M., Krtolica, A., Galimi, F., Narita, M., Lowe, S. W., Yaswen, P., & Campisi, J. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg417 · Cited by 1,457
Senescence-associated β-galactosidase is lysosomal β-galactosidase.
Lee, B. Y., Han, J. A., Im, J. S., Morrone, A., Johung, K., Goodwin, E. C., Kleijer, W. J., DiMaio, D., & Hwang, E. S. (2006) · Aging Cell · doi:10.1111/j.1474-9726.2006.00199.x · Cited by 1,444
Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen
Noda, A., Ning, Y., Venable, S. F., Pereira-Smith, O. M., & Smith, J. R. (1994) · Experimental Cell Research · doi:10.1006/excr.1994.1063 · Cited by 1,351
Longevity, Stress Response, and Cancer in Aging Telomerase-Deficient Mice
Rudolph, K. L., Chang, S., Lee, H.-W., Blasco, M., Gottlieb, G. J., Greider, C., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80580-2 · Cited by 1,349 · cited 1×
“Mice engineered to lack telomerase activity are tumor prone, and this is accelerated by p53 loss (Chin et al. 1999; Rudolph et al. 1999).”
BackgroundHerbig, U., Jobling, W. A., Chen, B. P. C., Chen, D. J., & Sedivy, J. M. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00256-4 · Cited by 1,344 · cited 1×
“Similar to cells that lack p53, normal HDFs that lack p21 also fail to arrest after serial passage (Brown et al. 1997; Herbig et al. 2004), and inactivation of p21 by injection of specific antibodies results in reinitiation of S phase (Ma et al. 1999).”
BackgroundSenescence in tumours: evidence from mice and humans
Collado, M., & Serrano, M. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2772 · Cited by 1,124 · cited 3×
“However, some questions were unaddressed, including when, during the transformation from normal cell to malignant cell, does p53mediated senescence act to prevent cancer and extend life span? Subsequent studies in mouse models and clinical specimens addressed this question, showing that cells driven to senescence by p…”
BackgroundForging a signature of in vivo senescence
Sharpless, N. E., & Sherr, C. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3960 · Cited by 1,104
A Senescence Program Controlled by p53 and p16INK4a Contributes to the Outcome of Cancer Therapy
Schmitt, C. A., Fridman, J. S., Yang, M., Lee, S., Baranov, E., Hoffman, R. M., & Lowe, S. W. (2002) · Cell · doi:10.1016/s0092-8674(02)00734-1 · Cited by 1,050
Chin, L., Artandi, S. E., Shen, Q., Tam, A., Lee, S.-L., Gottlieb, G. J., Greider, C. W., & DePinho, R. A. (1999) · Cell · doi:10.1016/s0092-8674(00)80762-x · Cited by 979 · cited 1×
“Mice engineered to lack telomerase activity are tumor prone, and this is accelerated by p53 loss (Chin et al. 1999; Rudolph et al. 1999).”
BackgroundLin, A. W., Barradas, M., Stone, J. C., van Aelst, L., Serrano, M., & Lowe, S. W. (1998) · Genes & Development · doi:10.1101/gad.12.19.3008 · Cited by 945
Wajapeyee, N., Serra, R. W., Zhu, X., Mahalingam, M., & Green, M. R. (2008) · Cell · doi:10.1016/j.cell.2007.12.032 · Cited by 903 · cited 10×
“It has now been thoroughly shown that many types of tumor cells made senescent by chemotherapy treatment produce cytokines and chemokines through the SASP (Coppe et al. 2008; Novakova et al. 2010; Jackson et al. 2012).”
BackgroundInfluentialKurz, D. J., Decary, S., Hong, Y., & Erusalimsky, J. D. (2000) · Journal of Cell Science · doi:10.1242/jcs.113.20.3613 · Cited by 899
p53-Dependent apoptosis suppresses tumor growth and progression in vivo
Symonds, H., Krall, L., Remington, L., Saenz-Robles, M., Lowe, S., Jacks, T., & Van Dyke, T. (1994) · Cell · doi:10.1016/0092-8674(94)90534-7 · Cited by 880 · cited 1×
“One of the best-characterized mechanisms of tumor suppression mediated by p53 is apoptotic cell death (Lowe et al. 1993; Symonds et al. 1994).”
BackgroundSenescence of human fibroblasts induced by oncogenic Raf
Zhu, J., Woods, D., McMahon, M., & Bishop, J. M. (1998) · Genes & Development · doi:10.1101/gad.12.19.2997 · Cited by 826
Therapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824 · cited 1×
“It is apparent from these in vitro studies that presence of wild-type p53 in many cancer cell lines can direct a senescent response after chemotherapy in vitro (Roninson 2002; Ewald et al. 2010).”
BackgroundMutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
A negative feedback signaling network underlies oncogene-induced senescence
Courtois-Cox, S., Genther Williams, S. M., Reczek, E. E., Johnson, B. W., McGillicuddy, L. T., Johannessen, C. M., Hollstein, P. E., MacCollin, M., & Cichowski, K. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.10.003 · Cited by 501 · cited 3×
“Additionally, loss of negative regulators of Ras and PI3 kinase, such as neurofibromatosis type 1 (NF1) (Courtois-Cox et al. 2006) and PTEN (Chen et al.”
BackgroundDose-dependent oncogene-induced senescence in vivo and its evasion during mammary tumorigenesis
Sarkisian, C. J., Keister, B. A., Stairs, D. B., Boxer, R. B., Moody, S. E., & Chodosh, L. A. (2007) · Nature Cell Biology · doi:10.1038/ncb1567 · Cited by 490 · cited 4×
“Potent inducible activation of H-RasG12V resulted in reduced mammary duct elongation in puberty followed by induction of senescence, as detected by p16, PML, and SA-bGal staining (Sarkisian et al. 2007).”
BackgroundInfluentialAccelerated ageing in mice deficient in Zmpste24 protease is linked to p53 signalling activation
Varela, I., Cadiñanos, J., Pendás, A. M., Gutiérrez-Fernández, A., Folgueras, A. R., Sánchez, L. M., Zhou, Z., Rodríguez, F. J., Stewart, C. L., Vega, J. A., et al. (2005) · Nature · doi:10.1038/nature04019 · Cited by 466 · cited 4×
“Mice null for both Zmpste24 and p53 no longer stained positive for SA-bGal in the kidney and had a longer life span than p53 wild-type, Zmpste24 null mice (Varela et al. 2005).”
BackgroundInfluentialInside and out: the activities of senescence in cancer
Pérez-Mancera, P. A., Young, A. R. J., & Narita, M. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3773 · Cited by 462 · cited 1×
“However, secretion of multiple cytokines and growth factors by the SASP can act via paracrine and autocrine signaling and can have protumorigenic effects on nearby cells (Velarde et al. 2013; Perez-Mancera et al. 2014).”
BackgroundChoudhury, A. R., Ju, Z., Djojosubroto, M. W., Schienke, A., Lechel, A., Schaetzlein, S., Jiang, H., Stepczynska, A., Wang, C., Buer, J., et al. (2007) · Nature Genetics · doi:10.1038/ng1937 · Cited by 426 · cited 1×
“In these mice, p21 loss impairs p53-mediated arrest and senescence, but leaves apoptosis intact (Choudhury et al. 2007).”
BackgroundHuman cell senescence as a DNA damage response
Zglinicki, T. V., Saretzki, G., Ladhoff, J., Fagagna, F. D. D., & Jackson, S. P. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2004.09.034 · Cited by 419 · cited 2×
“As telomeres shorten, eventually a DNA damage signal is detected (d’Adda di Fagagna et al. 2003; von Zglinicki et al. 2005) and a classical DNA damage response is initiated (von Zglinicki et al. 2005).”
BackgroundTelomere dysfunction and Atm deficiency compromises organ homeostasis and accelerates ageing
Wong, K.-K., Maser, R. S., Bachoo, R. M., Menon, J., Carrasco, D. R., Gu, Y., Alt, F. W., & DePinho, R. A. (2003) · Nature · doi:10.1038/nature01385 · Cited by 375 · cited 2×
“One step in this process is the activation of the ATM kinase (Wong et al. 2003), which phosphorylates both p53 and Mdm2 (Banin et al. 1998; Canman et al. 1998; Khanna et al. 1998; Maya et al. 2001), thus allowing the p53 protein to accumulate and initiate transcription of multiple target genes (Fig.”
BackgroundJackson, J. G., Pant, V., Li, Q., Chang, L. L., Quintás-Cardama, A., Garza, D., Tavana, O., Yang, P., Manshouri, T., Li, Y., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.027 · Cited by 329
Self-citationLiu, G., Parant, J. M., Lang, G., Chau, P., Chavez-Reyes, A., El-Naggar, A. K., Multani, A., Chang, S., & Lozano, G. (2004) · Nature Genetics · doi:10.1038/ng1282 · Cited by 325 · cited 3×
“This hypomorphic p53 protein still suppresses spontaneous tumor formation by a Cdkn1a-dependent mechanism (Liu et al. 2004; Barboza et al. 2006) and can also suppress Mycdriven lymphoma (Post et al.”
BackgroundSelf-citationIncreased activity of p53 in senescing fibroblasts
Atadja, P., Wong, H., Garkavtsev, I., Veillette, C., & Riabowol, K. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8348 · Cited by 308
Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J. (2008) · PLoS Biology · doi:10.1371/journal.pbio.0060301 · Cited by 302 · cited 1×
“Further, p53-mediated senescence suppresses tumors in mice with deprotected telomeres (Cosme-Blanco et al. 2007; Feldser and Greider 2007).”
BackgroundAstle, M. V., Hannan, K. M., Ng, P. Y., Lee, R. S., George, A. J., Hsu, A. K., Haupt, Y., Hannan, R. D., & Pearson, R. B. (2012) · Oncogene · doi:10.1038/onc.2011.394 · Cited by 295 · cited 2×
“1998), AKT (Astle et al. 2012), and PIK3CA (Kim et al.”
Cao, L., Li, W., Kim, S., Brodie, S. G., & Deng, C.-X. (2003) · Genes & Development · doi:10.1101/gad.1050003 · Cited by 293 · cited 2×
“When crossed into a p53 heterozygous null background, the developmental defects are completely rescued, no senescence is observed in the embryo, and mice can live 6 to 12 months (Cao et al. 2003).”
BackgroundOncogene-induced senescence: the bright and dark side of the response
Gorgoulis, V. G., & Halazonetis, T. D. (2010) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2010.07.013 · Cited by 257
Cosme‐Blanco, W., Shen, M., Lazar, A. J. F., Pathak, S., Lozano, G., Multani, A. S., & Chang, S. (2007) · The EMBO Reports · doi:10.1038/sj.embor.7400937 · Cited by 205 · cited 1×
“Further, p53-mediated senescence suppresses tumors in mice with deprotected telomeres (Cosme-Blanco et al. 2007; Feldser and Greider 2007).”
BackgroundSelf-citationSASP mediates chemoresistance and tumor-initiating-activity of mesothelioma cells
Canino, C., Mori, F., Cambria, A., Diamantini, A., Germoni, S., Alessandrini, G., Borsellino, G., Galati, R., Battistini, L., Blandino, R., et al. (2012) · Oncogene · doi:10.1038/onc.2011.485 · Cited by 200 · cited 1×
“Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a026112 9 w w w .p er sp ec ti ve si n m ed ic in e. o rg et al. 2012; Canino et al. 2012).”
BackgroundInfluentialSenescence-associated secretory phenotype favors the emergence of cancer stem-like cells
Cahu, J., Bustany, S., & Sola, B. (2012) · Cell Death & Disease · doi:10.1038/cddis.2012.183 · Cited by 160
Cytokine expression and signaling in drug-induced cellular senescence
Novakova, Z., Hubackova, S., Kosar, M., Janderova-Rossmeislova, L., Dobrovolna, J., Vasicova, P., Vancurova, M., Horejsi, Z., Hozak, P., Bartek, J., et al. (2010) · Oncogene · doi:10.1038/onc.2009.318 · Cited by 127 · cited 9×
“It has now been thoroughly shown that many types of tumor cells made senescent by chemotherapy treatment produce cytokines and chemokines through the SASP (Coppe et al. 2008; Novakova et al. 2010; Jackson et al. 2012).”
BackgroundInfluentialSenescent Cells and Their Secretory Phenotype as Targets for Cancer Therapy
Velarde, M. C., Demaria, M., & Campisi, J. (2013) · Interdisciplinary Topics in Gerontology and Geriatrics · doi:10.1159/000343572 · Cited by 112 · cited 1×
“However, secretion of multiple cytokines and growth factors by the SASP can act via paracrine and autocrine signaling and can have protumorigenic effects on nearby cells (Velarde et al. 2013; Perez-Mancera et al. 2014).”
BackgroundJackson, J. G., & Pereira-Smith, O. M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2501-2510.2006 · Cited by 108
Self-citationWei, W., Herbig, U., Wei, S., Dutriaux, A., & Sedivy, J. M. (2003) · The EMBO Reports · doi:10.1038/sj.embor.7400001 · Cited by 88 · cited 1×
“Cells with one allele targeted will spontaneously lose the second allele, avoid senescent arrest, and continue through the cell cycle into crisis with eventual emergence of immortal cell populations (Wei et al. 2003).”
BackgroundThe Rb/chromatin connection and epigenetic control: opinion
Ferreira, R., Naguibneva, I., Pritchard, L. L., Ait-Si-Ali, S., & Harel-Bellan, A. (2001) · Oncogene · doi:10.1038/sj.onc.1204337 · Cited by 76
Cited by
SASP: Tumor Suppressor or Promoter? Yes!
Rao, S. G., & Jackson, J. G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.10.001 · Cited by 206
Self-citationXu, P., Wang, M., Song, W.-M., Wang, Q., Yuan, G.-C., Sudmant, P. H., Zare, H., Tu, Z., Orr, M. E., & Zhang, B. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00507-7 · Cited by 114
Zhan, H., Xie, H., Zhou, Q., Liu, Y., & Huang, W. (2018) · ACS Synthetic Biology · doi:10.1021/acssynbio.8b00202 · Cited by 36
Senescence: A program in the road to cell elimination and cancer
Moiseeva, O., Guillon, J., & Ferbeyre, G. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.12.017 · Cited by 25
Role of Autophagy in Skin Photoaging: A Narrative Review
Zhong, X., Deng, Y., Yang, H., Du, X., Liu, P., & Du, Y. (2024) · Medicine · doi:10.1097/md.0000000000037178 · Cited by 18
“[85,86] It primarily functions as a cellular protective mechanism that requires rigorous regulation.”
Background
Metadata
- Authors
- Tonnessen-Murray, C. A., Lozano, G., & Jackson, J. G.
- Venue
- Cold Spring Harbor Perspectives in Medicine
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2016-11-23
- Volume
- 7
- Issue
- 2
- Pages
- a026112
- ISSN
- 2157-1422 (ISSN-L)
- OpenAlex
- W2551792087
- Cited by
- 70
- References
- 54
- Type
- posted content
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.